Navigation Links
Unilife Develops Proprietary Portfolio of Wearable Subcutaneous Infusion Devices for the Self-Administration of Large Volume Drugs by Patients

YORK, Pa., Sept. 12, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced the development of its AutoInfusor™ portfolio of subcutaneous infusion systems for the patient self-administration of drugs in 3mL, 5mL, 7mL, and 10mL volumes.

Unilife has developed its AutoInfusor technology to address the unmet needs of pharmaceutical and biotechnology companies with drugs that have complex formulations with higher viscosities and requiring large dose volumes. AutoInfusors are now available for supply to pharmaceutical companies for human clinical trials in either prefilled or fill-at-time-of-use formats.

AutoInfusors are compact, single-use drug delivery systems that are designed for simple, intuitive and convenient use by patients outside of healthcare facilities. Consisting of a primary drug container, fluid delivery path, and drive mechanism, AutoInfusors are modular in design and can be customized to address the specific requirement of the drug and its target patient. They can be pre-set for infusion periods that can span minutes or hours in duration, as specified by the pharmaceutical customer.

Once the patient attaches the device onto the injection site and pushes the activation button, the automatic infusion of the drug into the subcutaneous tissue commences. With the size, shape and functionality of the AutoInfusor being ergonomically designed for optimal wearability, the patient can continue to go about their normal daily routines during the period of dose delivery. A series of audible, tactile and visual indicators can signal to the patient when the full dose has been delivered, at which time the AutoInfusor can be removed from the body for convenient disposal.

Mr. Alan Shortall, CEO of Unilife said, "Our AutoInfusors represent the world's first and only subcutaneous infusion system ready for human clinical trials that can facilitate the patient self-administration of drugs between 3mL and 10mL in dose volume.

"Pharmaceutical companies are actively developing a significant number of pipeline drugs targeted for the treatment of acute, chronic and palliative diseases. Many of these emerging macro-molecule drugs, including a number of biologics, feature a complex formulation of proteins with higher viscosities that require large volume doses. The conventional patch pumps that have been developed for the delivery of drugs such as insulin are largely unsuitable for delivery of these drugs. Until now, pharmaceutical companies developing these complex drugs have lacked access to a single-use subcutaneous infusion system that can enable patients to easily self-administer doses greater than 3mL in volume.

"As the world's first and only known subcutaneous infusion systems available in a range of sizes including 3mL, 5mL, 7mL, and 10mL, our AutoInfusors represent breakthrough technology within this fast-growing and high-value sector for injectable drug delivery devices. For clinical trial purposes, the AutoInfusor can either be filled at the time of use for the convenience of pharmaceutical customers, or supplied in a prefilled format.

"With the development of our AutoInfusor technology platform, Unilife now has the most complete proprietary portfolio of injectable drug delivery devices. Our extensive and customer-focused portfolio of technology platforms includes our Unifill primary drug delivery systems with integrated safety features, patient self-injection devices including auto-injectors and subcutaneous infusion systems, as well as devices for targeted organ delivery. With Unilife, pharmaceutical and biotechnology companies now have the option of selecting a single partner in the development and commercial supply of innovative, differentiated devices that can help to enable, enhance and extend the commercial lifecycles of their injectable drugs and vaccines."

Pharmaceutical and biotechnology companies seeking additional information regarding the Unilife AutoInfusor can contact Unilife at

About Unilife CorporationUnilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.  For more information on Unilife, please visit 

Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission. 

General: UNIS-G Investor Contacts (US):Investor Contacts (Australia)Todd Fromer / Garth Russell

Stuart Fine

Jeff CarterKCSA Strategic Communications

Carpe DM Inc

Unilife CorporationP: + 1 212-682-6300

P: + 1 908 469 1788

P: + 61 2 8346 6500

SOURCE Unilife Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Unilife to Participate in Two Investor Conferences
2. Unilife COO to Again Purchase More Than $250,000 in Company Shares
3. Unilife Corporation Announces Preliminary Financial Results for the Fourth Quarter and Fiscal Year 2011
4. Unilife Develops Proprietary Range of Auto-Injectors for Patient Self-Administration of Injectable Drugs
5. Unilife Develops Unifill® EZMix Multiple-Chamber Prefilled Syringes
6. Unilife Signs $10 Million Equipment Financing Agreement
7. Unilife Expands Management Team to Support Business Growth
8. Unilife Starts Unifill Syringe Sales to Another Pharmaceutical Customer
9. Unilife Successfully Completes Industrialization of Unifill Syringe
10. Unilife Hosts White House Business Council Meeting
11. Unilife to Present at the 2011 Jefferies Global Healthcare Conference in New York City
Post Your Comments:
(Date:12/1/2015)... Russia has always been a country of choice for ... Europe in 2015 were tested in phase II-III ... has always been a country of choice for global multi-center phase ... in 2015 were tested in phase II-III clinical trials ... always been a country of choice for global multi-center phase III clinical ...
(Date:12/1/2015)... ANGELES , Dec. 1, 2015 CytRx ... development company specializing in oncology, today announced that it ... the company,s pivotal global Phase 3 clinical trial of ... (STS). Enrollment was originally estimated to be completed in Q1 ... being conducted under a Special Protocol Assessment from the ...
(Date:12/1/2015)... , Dec. 1, 2015  The migration to ... develop shared care plans that help patients stay ... plans will be digitally enabled, incorporate care guidelines ... and desires. They will also allow all stakeholders ... health journey is optimal. That is the vision, ...
Breaking Medicine Technology:
(Date:12/1/2015)... ... 01, 2015 , ... Physicians’ Education Resource®, LLC (PER®) ... announced that the first annual School of Gastrointestinal Oncology™ (SOGO™) will be held ... treatment of gastrointestinal cancers are undergoing transformational change, providing oncologists with powerful new ...
(Date:12/1/2015)... ... December 01, 2015 , ... Speech and ... believe that with innovative technologies and under the right circumstances, these practices can ... benefit of a dual-approach to his or her therapeutic sessions, as well as ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... the 7th Annual 2015 Golden Bridge Business Awards under the New Products and ... zero capex web based sample management software that helps labs organize ...
(Date:12/1/2015)... ... December 01, 2015 , ... The importance of volumetric ... the focus of numerous abstracts accepted for presentation here, at the 101st Annual ... abstracts highlight the use of Volpara Solutions’ quantitative breast imaging software tools for ...
(Date:12/1/2015)... ... December 01, 2015 , ... SAN FRANCISCO, Calif. ... that the organization has awarded Education and Developmental Therapies (EDT), an Applied Behavior ... award celebrates exceptional special needs providers that excel in synthesizing the areas of ...
Breaking Medicine News(10 mins):